Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer source : Contravir.com save search
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies
Published: 2023-01-18 (Crawled : 14:20) - contravir.com
HEPA | $2.1118 -0.85% -1.43% 6
|
Health Technology
|
| O: -2.83%
H: 5.93%
C: -22.41%
preclinical potential results cancer
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Published: 2021-11-16 (Crawled : 14:00) - contravir.com
HEPA | $2.1118 -0.85% -1.43% 6
|
Health Technology
|
| O: 2.07%
H: 0.0%
C: 0.0%
cancer liver crv431 preclinical
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
Published: 2021-11-10 (Crawled : 13:00) - contravir.com
HEPA | $2.1118 -0.85% -1.43% 6
|
Health Technology
|
| O: 3.11%
H: 0.67%
C: -2.01%
cancer research liver crv431
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
THCH | News | $1.28 23.08% 13.33% 79K
|
n/a
UMAC | $1.55 0.65% 12.9% 0
|
Your saved searches
Save your searches and get alerts when important news are released.